Minerva Neurosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $183.52M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 7, 2026 | Before market open | – | $-0.14 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | – | $-2.86 | $-0.17 |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 11, 2026 | Before market open | – | $-25.51 | $-0.64 |
| Q4 FY2014 Ended Dec 31, 2014 | Mar 26, 2015 | During market hours | – | – | – |
| Q3 FY2014 Ended Sep 30, 2014 | Nov 6, 2014 | During market hours | – | – | – |
| Q2 FY2014 Ended Jun 30, 2014 | Aug 7, 2014 | During market hours | – | – | – |
Press releases
Announcements Minerva Neurosciences filed with the SEC
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Minerva Neurosciences Provides First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Jim O’Connor joins as Chief Business Officer and General Counsel
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Minerva Neurosciences Announces Financing of up to $200 Million to Advance
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for
Other events · EX-99.1 to Form 8-K
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the
Other events · EX-99.1 to Form 8-K
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the
Other events · EX-99.1 to Form 8-K
Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative
Other events · EX-99.1 to Form 8-K
Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for
Other events · EX-99.1 to Form 8-K
Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in
Other events · EX-99.1 to Form 8-K
Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of
Other events · EX-99.1 to Form 8-K